A multi-national study of the use, safety and effectiveness of smoking cessation pharmacotherapies during pregnancy
DATE
Time to AEST
Event Series External event
Location Online
In this webinar, presenters Dr Alys Havard and Dr Danielle Tran from the National Drug and Alcohol Research Centre (NDARC) will describe their current program of research.
They have been examining the use, safety and effectiveness of prescription varenicline, nicotine replacement therapy and bupropion during pregnancy. These research questions will be addressed with population-based cohort studies using linked data from Australia, New Zealand, Norway and Sweden. Findings regarding the risk of congenital malformations in babies exposed to these pharmacotherapies during gestation will be presented.
Tobacco Endgame is a member of the Collaboration for Enhanced Research Impact (CERI).
About CERI
The Collaboration for Enhanced Research Impact (CERI) is a joint initiative between the Prevention Centre and several NHMRC Centres of Research Excellence, established in June 2020 to enhance the profile and impact of chronic disease prevention in Australia. We are working together to find alignment in the policy and practice implications of our work and to develop shared communications across our various projects and participating centres.
